[1] |
Chinese Antituberculosis Association, Schools and Children Branch of the Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis .
Expert consensus of clinical application of the recombinant Mycobacterium tuberculosis fusion protein (EC)
[J]. Chinese Journal of Antituberculosis, 2020, 42(8): 761-768.
|
[2] |
YANG Lei, WEI Fen, ZHANG Kai, QIU Jing-jing, WANG Ying-ying, DU Wei-xin, LU Jin-biao, TAO Li-feng, PU Jiang.
Stability and efficacy study of recombinant Mycobacterium tuberculosis fusion protein (EC)
[J]. Chinese Journal of Antituberculosis, 2020, 42(8): 799-806.
|
[3] |
ZHANG Kai, TAO Li-feng, WEI Fen, DU Wei-xin, QIU Jing-jing, CHEN Wei, CHEN Bao-wen, ZHU Yin-meng, CHENG Xing, SU Cheng, ZHONG Zai-xin, LU Jin-biao, PU Jiang.
Immune characteristics and preclinical animal safety studies of recombinant Mycobacterium tuberculosis fusion protein(EC)
[J]. Chinese Journal of Antituberculosis, 2020, 42(8): 807-813.
|
[4] |
YANG Lu-qi, SHEN Ming-yi, SHA Wei, CHEN Ying-ying, WANG Ying.
Research progress in immunoprotective mechanism of bacille Calmette-Guérin and vaccine development strategies
[J]. Chinese Journal of Antituberculosis, 2020, 42(8): 863-868.
|
[5] |
SUN Qing, HUANG Hai-rong, WANG Gui-rong.
In vitro activities and drug resistance mechanisms of bedaquiline, clofazimine and delamanid against common pathogenic non-tuberculous mycobacteria
[J]. Chinese Journal of Antituberculosis, 2020, 42(8): 880-884.
|
[6] |
ZHAO Jiao-jie,FU Lei,WANG Bin,ZHANG Lei,HU Ming-hao,LU Yu.
Establishment and application of pharmacodynamics and pharmacokinetics model in vitro
[J]. Chinese Journal of Antituberculosis, 2020, 42(4): 372-379.
|
[7] |
YING Ruo-yan, HUANG Xiao-chen, WANG Jie, LIU Yi-dian, SHA Wei, YANG Hua.
Clinical analysis of drug sensitivity tests of various drug-resistant MTB isolates against different combinations of anti-tuberculosis drugs in vitro
[J]. Chinese Journal of Antituberculosis, 2020, 42(11): 1183-1182.
|
[8] |
LIU Er-yong, ZHOU Lin, XUE Xiao, LIU Chun-fa, BAI Li-qiong, LU Wei, ZHANG Tian-hua, CHENG Shi-ming.
Evaluation of treatment effect and safety of rifampicin capsule (Ⅱ) on pulmonary tuberculosis
[J]. Chinese Journal of Antituberculosis, 2020, 42(10): 1092-1099.
|
[9] |
QIU Qian,YANG Song,CHEN Yong,XU Xiao-ming,YANG Zai-xing.
Antibacterial effect of sulfur heteroarotinoid A2 on Mycobacterium tuberculosis in vitro and in vivo
[J]. Chinese Journal of Antituberculosis, 2019, 41(11): 1155-1159.
|
[10] |
ZHANG Ye,LI Yuan-yuan,XU Jian,CHEN Xi,WANG Bin,FU Lei,LU Yu.
Preliminary study on the action mechanism of TBI-166 against drug-resistant Mycobacterium tuberculosis
[J]. Chinese Journal of Antituberculosis, 2019, 41(11): 1160-1166.
|
[11] |
Jing WANG,Wei JING,Wei CHEN,Ru GUO,Xi-qin HAN,li-min WU,Guang-xu YANG,Kun-yun YANG,Cong CHEN,Lin JIANG,Chun-kui CAI,Zhi DOU,Li-juan DIAO,Hong-qiu PAN,Jian-yun WANG,Fei-fei DU,Li-xia WANG,Ren-zhong LI,Nai-hui CHU.
Analysis on the adverse events among multidrug-resistant pulmonary tuberculosis patients receiving cycloserine-containing regimen
[J]. Chinese Journal of Antituberculosis, 2018, 40(8): 810-814.
|
[12] |
Fei REN,You XU,Li-yun DANG,Yan-qin WU,Jin-bao MA,Si-si. ZHENG.
Observation and comparative analysis on the adverse drug reactions of amikacin and capreomycin in treating multidrug resistant tuberculosis patients
[J]. Chinese Journal of Antituberculosis, 2018, 40(8): 815-820.
|
[13] |
Cun-bing GUO,Hui LI,Shu-lan ZHENG.
Treatment effect of Shenqi Eleven Granules on leuccytopenia caused by antituberculosis drugs
[J]. Chinese Journal of Antituberculosis, 2018, 40(3): 274-279.
|
[14] |
JIANG Jun.
Quality control and quality assurance of T-SPOT.TB
[J]. Chinese Journal of Antituberculosis, 2014, 36(5): 380-384.
|
[15] |
WU Long-zhang,LIU Yan-wen,ZHONG Bing-tang.
Laboratory examination and quality control of Mycobacterium
[J]. Chinese Journal of Antituberculosis, 2014, 36(4): 286-289.
|